Incidence of Lymph Node Involvement in Clinically Node-Negative Breast Cancer Following Neoadjuvant Chemotherapy: Rationale for Selective Omission of Sentinel Lymph Node Biopsy
Clinical Breast Cancer · 2025
DOI: 10.1016/j.clbc.2025.03.021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Breast Cancer, 2025. Verfasst von Arith Reyes und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Breast Surgery Division, Columbia University Medical Center, New York, NY. Electronic address: arr2242@cumc.columbia.edu. Hauptthemen laut MEDLINE: Breast Neoplasms, Sentinel Lymph Node Biopsy, Lymph Nodes, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, Breast Surgery Division, Columbia University Medical Center, New York, NY. Electronic address: arr2242@cumc.columbia.edu.
- Department of Surgery, Breast Surgery Division, Columbia University Medical Center, New York, NY.
Zitieren
APA
Reyes, A., Rao, R., Wiechmann, L., Sun, L., Ugras, S., & Taback, B. (2025). Incidence of Lymph Node Involvement in Clinically Node-Negative Breast Cancer Following Neoadjuvant Chemotherapy: Rationale for Selective Omission of Sentinel Lymph Node Biopsy. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2025.03.021
Vancouver
Reyes A, Rao R, Wiechmann L, Sun L, Ugras S, Taback B. Incidence of Lymph Node Involvement in Clinically Node-Negative Breast Cancer Following Neoadjuvant Chemotherapy: Rationale for Selective Omission of Sentinel Lymph Node Biopsy. Clinical Breast Cancer. 2025. doi:10.1016/j.clbc.2025.03.021
BibTeX
@article{Reyes2025,
author = {Reyes, Arith and Rao, Roshni and Wiechmann, Lisa and Sun, Luona and Ugras, Stacy and Taback, Bret},
title = {Incidence of Lymph Node Involvement in Clinically Node-Negative Breast Cancer Following Neoadjuvant Chemotherapy: Rationale for Selective Omission of Sentinel Lymph Node Biopsy},
journal = {Clinical Breast Cancer},
year = {2025},
doi = {10.1016/j.clbc.2025.03.021}
}
EUVIMED